Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …

Melanoma is the most aggressive and dangerous form of skin cancer that develops from
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …

Metabotropic glutamate (mGlu) receptors were discovered in the mid 1980s and originally
described as glutamate receptors coupled to polyphosphoinositide hydrolysis. Almost 6500 …

Drug repositioning (also referred to as drug repurposing), the process of finding new uses of
existing drugs, has been gaining popularity in recent years. The availability of several …

This review aims to summarize the current knowledge of molecular pathways and their
clinical relevance in melanoma. Metastatic melanoma was a grim diagnosis, but in recent …

Background A sensitive assay to identify biomarkers using non-invasively collected clinical
specimens is ideal for breast cancer detection. While there are other studies showing …

In recent years, phosphonic acids and their derivatives have received increasing attention
as analogues of a series of naturally occurring phosphates and as “bio-isosteric phosphorus …

One approach to speed up drug discovery is to examine new uses for existing approved
drugs, so-called 'drug repositioning'or 'drug repurposing', which has become increasingly …

Glutamate, as one of the most important carbon sources in the TCA cycle, is central in
metabolic processes that will subsequently influence tumor progression. Several factors can …

Riluzole, a glutamate release inhibitor, has been in use for the treatment of amyotrophic
lateral sclerosis for over two decades since its approval by the Food and Drug …